Placental growth factor (PlGF): A key to optimizing fetal growth

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 26, Issue 10, 2013, Pages 995-1002

  Vrachnis, Nikolaos ^a   Kalampokas, Emmanouil ^a   Sifakis, Stavros ^b   Vitoratos, Nikolaos ^a   Kalampokas, Theodoros ^a   Botsis, Demetrios ^a   Iliodromiti, Zoe ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Angiogenesis; Fetal growth; Fms like tyrosine kinase 1; Kinase inserted domain receptor; Placental growth factor; Vascular endothelial growth factor

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADVERSE OUTCOME; ANGIOGENESIS; ARTICLE; FETUS DEVELOPMENT; FETUS GROWTH; HUMAN; INTRAUTERINE GROWTH RETARDATION; MATERNAL AGE; MATERNAL BLOOD; MATERNAL HYPERTENSION; OXYGEN TENSION; PLACENTA CIRCULATION; PLACENTA DEVELOPMENT; PLACENTA DISORDER; PREECLAMPSIA; PREGNANCY OUTCOME; PRENATAL SCREENING; PRIORITY JOURNAL; SMALL FOR DATE INFANT; SPONTANEOUS ABORTION; TROPHOBLAST;

ANIMALS; FEMALE; FETAL DEVELOPMENT; FETAL GROWTH RETARDATION; HUMANS; MODELS, BIOLOGICAL; PREGNANCY; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84878929497     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2013.766694     Document Type: Article

References (80)

1. Torry RJ, Rongish BJ. Angiogenesis in the uterus: potential regulation and relation to tumor angiogenesis. Am J Reprod Immunol 1992;27:171-9.
2. Botsis D, Vrachnis N, Christodoulakos G. Doppler assessment of the intrauterine growth-restricted fetus. Ann N Y Acad Sci 2006; 1092:297-303. (Pubitemid 47092347)
3. Vrachnis N, Vitoratos N, Iliodromiti Z, et al. Intrauterine inflammation and preterm delivery. Ann N Y Acad Sci 2010; 1205:118-22.
4. Malamitsi-Puchner A, Vrachnis N, Samoli E, et al. Investigation of midtrimester amniotic fluid factors as potential predictors of term and preterm deliveries. Mediators Inflamm 2006;2006:94381.
5. Khalil A, Muttukrishna S, Harrington K, et al. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS ONE 2008;3:e2766.
6. Poole TJ, Coffin JD. Vasculogenesis and angiogenesis: two distinct morphogenetic mechanisms establish embryonic vascular pattern. J Exp Zool 1989;251:224-31. (Pubitemid 19216058)
7. Guo S, Colbert LS, Fuller M, et al. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta 2010; 1806:108-21.
8. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995;11:73-91. (Pubitemid 26019602)
9. Flamme I, Frolich T, Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol 1997; 173:206-10. (Pubitemid 27481131)
10. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055-66. (Pubitemid 29233137)
11. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14.
12. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008;8:604-17.
13. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618-31.
14. Vincent KA, Shyu KG, Luo Y, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000;102:2255-61.
15. King BF. Ultrastructural differentiation of stromal and vascular components in early macaque placental villi. Am J Anat 1987; 178:30-44. (Pubitemid 17233916)
16. Zeng G, Taylor SM, McColm JR, et al. Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood 2007;109:1345-52. (Pubitemid 46239563)
17. Breunis WB, Davila S, Shimizu C, et al. International Kawasaki Disease Genetics Consortium. Disruption of vascular homeostasis in Kawasaki Disease patients: involvement of vascular endothelial growth factor and angiopoietins. Arthritis Rheum 2012;64:306-15.
18. Torry DS, Hinrichs M, Torry RJ. Determinants of placental vascularity. Am J Reprod Immunol 2004;51:257-68. (Pubitemid 38455727)
19. Koch S, Tugues S, Li X, et al. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011;437:169-83.
20. De Vries C, Escobedo JA, Ueno H, et al. The Fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-91.
21. Matthews W, Jordan CT, Gavin M, et al. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 1991;88:9026-30. (Pubitemid 21915561)
22. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (Flt) closely related to the Fms family. Oncogene 1993;5:519-24.
23. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nature Med 2009;15:1023-30.
24. Wallner W, Sengenberger R, Strick R. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007;112:51-7. (Pubitemid 46120085)
25. Ahmad S, Hewett PW, Al-Ani B, et al. Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vasc Cell 2011;3:15.
26. McDonald NQ, Hendrickson WA. A structural superfamily of growth factors containing a cystine knot motif. Cell 1993;73:421-4. (Pubitemid 23143340)
27. Vihinen PP, Ramadan S, Vuoristo MS, et al. Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. Melanoma Res 2011;21:431-7.
28. Shiraishi S, Nakagawa K, Kinukawa N, et al. Immunohistochemical localization of vascular endothelial growth factor in the human placenta. Placenta 1996;17:111-21. (Pubitemid 26117214)
29. Ghosh SK, Raheja S, Tuli A, et al. Serum PlGF as a potential biomarker for predicting the onset of preeclampsia. Arch Gynecol Obstet 2011;285:417-22.
30. Maglione D, Guerriero V, Viglietto G, et al. Two alternative messenger-RNAs coding for the angiogenic factor, placenta growth-factor (PlGF), are transcribed from a single gene of chromosome-14. Oncogene 1993;8:925-31. (Pubitemid 23087424)
31. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991;88:9267-71. (Pubitemid 21915612)
32. Iyer S, Leonidas DD, Swaminathan GJ, et al. The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution. J Biol Chem 2001;276:12153-61.
33. Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 1996;271:3154-62. (Pubitemid 26060529)
34. Shore VH, Wang TH, Wang CL, et al. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997;18:657-65. (Pubitemid 27448423)
35. Vuorela P, Hatva E, Lymboussaki A, et al. Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 1997;56:489-94. (Pubitemid 27081593)
36. Odorisio T, Cianfarani F, Failla CM, Zambruno G. The placenta growth factor in skin angiogenesis. J Dermatol Sci 2006;41:11-19. (Pubitemid 43075428)
37. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993;9:259-68. (Pubitemid 24034347)
38. Ziche M, Maglione D, Ribatti D, et al. Placenta growth factor-1 is chemotactic, mitogenic and angiogenic. Lab Invest 1997;76:517-31. (Pubitemid 27176106)
39. Parelman N, Selvaraj SK, Batra S, et al. Placenta growth factor activates monocytes ABD correlates in sickle cell disease severity. Blood 2003;102:1506-14. (Pubitemid 36988063)
40. Seung-Ah Y, Hyung-Ju Y, Hyun-Sook K, et al. Role of placenta growth factor and its receptor Flt-1 in rheumatoid inflammation. Arthritis Rheum 2009;60:345-54.
41. Koch AE. Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998;41:951-62. (Pubitemid 28265398)
42. Ferrara NH, Gerber P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
43. Yoo SA, Bae DG, Ryoo JW, et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen- induced arthritis and VEGF-stimulated productions of TNF-a and IL-6 by human monocytes. J Immunol 2005; 174:5846-55.
44. Oura H, Bertoncini J, Velasco P, et al. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 2003;101:560-7. (Pubitemid 36077578)
45. Selvaraj SK, Giri RK, Parelman N, et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003;102:1515-24. (Pubitemid 36988064)
46. Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) and soluble Flt-1 by oxygen: a review. Placenta 2000;21:16-24.
47. Khaliq A, Dunk C, Jiang J, et al. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab Invest 1999;79:151-70. (Pubitemid 29110646)
48. Thieme H, Aiello LP, Takagi H, et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 1993;44:98-103.
49. Taylor CM, Stevens H, Anthony FW, Wheeler T. Influence of hypoxia on vascular endothelial growth factor and chorionic gonadotrophin production in the trophoblast-derived cell lines: JEG, JAr and BeWo. Placenta 1997;18:451-8. (Pubitemid 27326316)
50. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J 1992;6:886-92.
51. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235:442-7. (Pubitemid 17009577)
52. Demir R, Kaufmann P, Castellucci M, et al. Fetal vasculogenesis and angiogenesis in human placental villi. Acta Anat (Basel) 1989;136:190-203. (Pubitemid 20045105)
53. Asan E, Kaymaz FF, Cakar AN, et al. Vasculogenesis in early human placental villi: an ultrastructural study. Anat Anz 1999; 181:549-54.
54. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig 2004;11:342-52. (Pubitemid 39185874)
55. Higgins M, McAuliffe F. A review of maternal and fetal growth factors in diabetic pregnancy. Curr Diabetes Rev 2010;6:116-25.
56. Malamitsi-Puchner A, Economou E, Boutsikou T, et al. Neurotrophin-3 and FLT3 tyrosine kinase receptor in perinatal life. Mediators Inflamm 2005;2005:53-6. (Pubitemid 40942911)
57. Muetze S, Kapagerof A, Vlachopoulos L, et al. Mutation analysis of the growth factor genes PlGF, Flt1, IGF-I, and IGF-IR in intrauterine growth restriction with abnormal placental blood flow. J Matern Fetal Neonatal Med 2010;23:142-7.
58. Myatt L. Role of placenta in preeclampsia. Endocrine 2002; 19:103-11. (Pubitemid 36106256)
59. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003;69:1-7. (Pubitemid 36806800)
60. Zhou Y, Damsky OH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997;99:2152-64.
61. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008;51:970-5. (Pubitemid 351398986)
62. Chaiworapongsa T, Romero R, Savasan ZA, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24:1187-207.
63. Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA 2002;287:3183-6. (Pubitemid 34686089)
64. Soto E, Romero R, Kusanovic JP, et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 2012;25:498-507.
65. Vrachnis N, Botsis D, Iliodromiti Z. The fetus that is small for gestational age. Ann N Y Acad Sci 2006;1092:304-9. (Pubitemid 47092348)
66. Su YN, Lee ON, Oheng WF, et al. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001;97:898-904. (Pubitemid 32522485)
67. Tidwell SO, Ho HN, Ohiu WH, et al. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001;184:1267-72.
68. Teixeira PG, Oabral AO, Andrade SP, et al. Placental growth factor (PlGF) is a surrogate marker in preeclamptic hypertension. Hypertens Pregnancy 2008;27:65-73. (Pubitemid 351302216)
69. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83. (Pubitemid 38364626)
70. Kusanovic JP, Romero R, Ohaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021-38.
71. Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012;25:2651-7.
72. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911-19.
73. Vandenberghe G, Mensink I, Twisk JW, et al. First trimester screening for intra-uterine growth restriction and early-onset preeclampsia. Prenat Diagn 2011;31:955-61.
74. Tjoa ML, van Vugt JM, Mulders MA, et al. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98:600-7. (Pubitemid 32907454)
75. Staff AC, Harsem NK, Braekke K, et al. Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies. Eur J Obstet Gynecol Reprod Biol 2009; 143:29-33.
76. Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-82. (Pubitemid 36135616)
77. Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble Fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89:770-5. (Pubitemid 38269892)
78. Poon LC, Zaragoza E, Akolekar R, et al. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008;28:1110-15.
79. Cowans NJ, Stamatopoulou A, Matwejew E, et al. First-trimester placental growth factor as a marker for hypertensive disorders and SGA. Prenat Diagn 2010;30:565-70.
80. Kalampokas E, Vrachnis N, Samoli E, et al. Association of adiponectin and placental growth factor in amniotic fluid with second trimester fetal growth. In Vivo 2012; 26:327-33.